Piomic Medical has developed the COMS One therapy system that promotes wound healing in chronic leg and foot ulcers.
Driven by diabetes and the effects of an ageing population, hard-to-heal wounds remain a major challenge for modern healthcare systems.
For example, approximately 1% of the population suffers from venous, arterial or mixed ulcers. And diabetic foot ulcers are a common complication of diabetes and affect up to 25% of the diabetic population, making diabetes the leading cause of major amputations.
Chronic cutaneous ulcers are defined as wounds which fail to proceed through phases of healing in an orderly and timely manner to produce durable structural functional and cosmetic closure. Macro and microvascular disorders are some of the most frequent causes for a delayed wound healing process.
The Swiss startup Piomic Medical has developed the COMS One therapy system. It is intended to promote wound healing in chronic leg and foot ulcers, for which the company has already obtained regulatory approval in Europe. The easy-to-use device is locally applied to the wound area, for 16 minutes 2-3 times per week over 6-8 weeks, in outpatient and home-care settings.
The COMS One therapy system combines technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of LED in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectrum. Magnetic stimulation is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectrum.
Backed by strong initial data and adoption by healthcare professionals, Piomic continues its clinical work on on the efficacy of optical and magnetic stimulation in chronic wounds. Having successfully concluded a multi-center clinical trial in Switzerland in the outpatient setting, a multi-center pivotal trial in the US now follows.
This is an innovative company combining two technologies for a novel therapeutic approach to address significant unmet needs in chronic wound care. And that is why we have invested in this startup.
